Please login to the form below

Not currently logged in
Email:
Password:

Lovaza

This page shows the latest Lovaza news and features for those working in and with pharma, biotech and healthcare.

GSK holds on to older products

GSK holds on to older products

Lovaza is one of several of GSK's drugs in its established products portfolio. ... The decline was primarily due to the onset of generic competition for the company's fish oil drug Lovaza, which is approved to lower levels of triglycerides and reduce the

Latest news

  • FDA approves AZ’s fish oil drug FDA approves AZ’s fish oil drug

    Once launched Epanova will enter a competitive for market for hypertriglyceridemia medicines, including BASF/Pronova's Omacor/Lovaza, another omega-3 fatty acid product. ... Omacor/Lovaza achieved end-user sales of around $1.4bn in 2011 and is sold by

  • Teva launches first generic of GSK's Lovaza in US Teva launches first generic of GSK's Lovaza in US

    Teva launches first generic of GSK's Lovaza in US. Will have six months of marketing exclusivity for copy of cardiovascular drug. ... GSK acquired US rights to Lovaza - which was originally developed by Norway's Pronova BioPharma - when it took over

  • GSK starts recovery from China crisis as growth returns GSK starts recovery from China crisis as growth returns

    That prediction disappointed some analysts, although it is thought to be a conservative estimate based on potential generic competition to older products such as cardiovascular drug Lovaza (omega-3-acid ethyl

  • Amarin slides as FDA panel votes against fish oil therapy Amarin slides as FDA panel votes against fish oil therapy

    One of the claims made by Amarin for Vascepa is that it reduces triglycerides without raising LDL-C, which could differentiate it from Lovaza/Omacor (omega-3-acid ethyl esters), another ... Lovaza sales in the first half of this year were around $500m

  • Witty says Chinese bribery probe will impact GSK Witty says Chinese bribery probe will impact GSK

    Generic rivals impacted epilepsy treatment Lamictal (lamotrigine), down 8 per cent to £63m, while heart disease drug Lovaza (omega-3-acid ethyl esters) held firm at £161m despite competition.

More from news
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2012 Pharma deals during November 2012

    Pronova supplies the active ingredient in GSK's triglyceride lowering omega-3 drug Lovaza and, in addition, is developing competitor formulations – the most advanced being PRC-4016 for dyslipidaemia. ... 900. Pronova BioPharma / BASF. Acquisition. Omega

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics